# TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

> **NCT00442832** · PHASE2 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 203 (actual)

## Conditions studied

- Staphylococcal Skin Infection

## Interventions

- **DRUG:** TD-1792
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT00442832
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442832, "TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00442832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*